ClinConnect ClinConnect Logo
Search / Trial NCT05224791

A Retrospective Multicenter Comparison of Laparoscopic and Robotic-Assisted Roux-en-Y Gastrectomy

Launched by METHODIST HEALTH SYSTEM · Feb 3, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Sleeve Gastrectomy Laparoscopic Robotic Assisted Rygb

ClinConnect Summary

This clinical trial is comparing two types of weight-loss surgery: laparoscopic (minimally invasive) and robotic-assisted Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). The study aims to find out which method is more effective for people struggling with obesity, a condition that affects a significant portion of the population. Weight-loss surgery can help many patients achieve lasting weight reduction and improve related health issues, such as diabetes or high blood pressure.

To participate in this trial, individuals must be at least 18 years old and have undergone either laparoscopic or robotic-assisted RYGB or SG between a specific timeframe. Eligible participants should have a body mass index (BMI) of over 40 or a BMI over 35 with related health problems. Those who had emergency surgeries or revision surgeries for their weight loss are not eligible. Patients joining the study can expect to contribute their experiences and outcomes to help improve future weight-loss surgery techniques.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject was 18 years or older at the time of procedure
  • Subject who has undergone either laparoscopic or robotic-assisted RYGB or SG between the time frame of 30 days prior to institution's IRB approval date and the year 2017
  • * Subject has one of the below qualifications:
  • 1. Body mass index (BMI) \> 40 kg/m2 or more than 100 pounds overweight OR
  • 2. BMI \> 35 kg/m2 and one of the following obesity-related co-morbidities such as type II diabetes mellitus, hypertension, sleep apnea and other respiratory disorders, non- alcoholic fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or heart disease.
  • Exclusion Criteria:
  • Subject who underwent RYGB or SG as an emergent procedure
  • Subject who underwent RYGB or SG as revisional bariatric procedure
  • Subject who underwent RYGB or SG as a secondary (concomitant) procedure and not as a primary procedure

About Methodist Health System

Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.

Locations

Dallas, Texas, United States

Patients applied

0 patients applied

Trial Officials

Sachin S Kukreja, MD

Principal Investigator

The Methodist Hospital Research Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials